R&D The glimmer of opportunity behind the storm: Ali Pashazadeh ... Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.
R&D The impact of generative AI on protein design for drug disco... Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.
R&D Changing the drug development treatment paradigm: Hilary Eat... Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.
R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
R&D Increasing trial efficiency: Adityo Prakash talks small data... Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
